JPWO2019191026A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191026A5 JPWO2019191026A5 JP2020551992A JP2020551992A JPWO2019191026A5 JP WO2019191026 A5 JPWO2019191026 A5 JP WO2019191026A5 JP 2020551992 A JP2020551992 A JP 2020551992A JP 2020551992 A JP2020551992 A JP 2020551992A JP WO2019191026 A5 JPWO2019191026 A5 JP WO2019191026A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- rna virus
- keratitis
- related disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 241001493065 dsRNA viruses Species 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 206010023332 keratitis Diseases 0.000 claims 8
- 206010006448 Bronchiolitis Diseases 0.000 claims 5
- PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 claims 5
- 230000001575 pathological effect Effects 0.000 claims 5
- 201000008197 Laryngitis Diseases 0.000 claims 4
- 230000005713 exacerbation Effects 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 201000007100 Pharyngitis Diseases 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 3
- 201000009890 sinusitis Diseases 0.000 claims 3
- 206010044008 tonsillitis Diseases 0.000 claims 3
- 241000711920 Human orthopneumovirus Species 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000005507 spraying Methods 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- 206010065837 External ear inflammation Diseases 0.000 claims 1
- 208000034619 Gingival inflammation Diseases 0.000 claims 1
- 206010023335 Keratitis interstitial Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010065838 Middle ear inflammation Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 206010028741 Nasal inflammation Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 206010044302 Tracheitis Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 238000012387 aerosolization Methods 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- SMBQBQBNOXIFSF-UHFFFAOYSA-N dilithium Chemical class [Li][Li] SMBQBQBNOXIFSF-UHFFFAOYSA-N 0.000 claims 1
- 239000012738 dissolution medium Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000005069 ears Anatomy 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000000744 eyelid Anatomy 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 201000006904 interstitial keratitis Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000008263 liquid aerosol Substances 0.000 claims 1
- 229910003002 lithium salt Inorganic materials 0.000 claims 1
- 159000000002 lithium salts Chemical class 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000004530 micro-emulsion Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000282 nail Anatomy 0.000 claims 1
- 239000007908 nanoemulsion Substances 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000003826 superficial keratitis Diseases 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- -1 suspending Substances 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023035224A JP7745584B2 (ja) | 2018-03-27 | 2023-03-08 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2025076718A JP2025118771A (ja) | 2018-03-27 | 2025-05-02 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648585P | 2018-03-27 | 2018-03-27 | |
| US62/648,585 | 2018-03-27 | ||
| US201862693021P | 2018-07-02 | 2018-07-02 | |
| US62/693,021 | 2018-07-02 | ||
| PCT/US2019/023977 WO2019191026A2 (en) | 2018-03-27 | 2019-03-26 | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023035224A Division JP7745584B2 (ja) | 2018-03-27 | 2023-03-08 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021519315A JP2021519315A (ja) | 2021-08-10 |
| JPWO2019191026A5 true JPWO2019191026A5 (https=) | 2022-04-01 |
| JP2021519315A5 JP2021519315A5 (https=) | 2022-04-01 |
| JP7242696B2 JP7242696B2 (ja) | 2023-03-20 |
Family
ID=66647439
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551992A Active JP7242696B2 (ja) | 2018-03-27 | 2019-03-26 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2023035224A Active JP7745584B2 (ja) | 2018-03-27 | 2023-03-08 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2025076718A Pending JP2025118771A (ja) | 2018-03-27 | 2025-05-02 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023035224A Active JP7745584B2 (ja) | 2018-03-27 | 2023-03-08 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
| JP2025076718A Pending JP2025118771A (ja) | 2018-03-27 | 2025-05-02 | ５’－アデノシン二リン酸リボース（ａｄｐｒ）の使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US10946034B2 (https=) |
| EP (2) | EP4226971A1 (https=) |
| JP (3) | JP7242696B2 (https=) |
| ES (1) | ES2949441T3 (https=) |
| WO (1) | WO2019191026A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622656B1 (ko) | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| CN111714619B (zh) * | 2020-07-15 | 2023-03-14 | 上海市浦东新区人民医院 | 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用 |
| CN112972453B (zh) * | 2021-03-05 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | MDL-800在制备抑制SARS-CoV-2病毒易感性药物中的应用 |
| KR102789553B1 (ko) * | 2021-09-07 | 2025-04-03 | 주식회사 펄스인마이어스 | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |
| WO2025122455A1 (en) * | 2023-12-04 | 2025-06-12 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) for vegf modulation |
| WO2025259632A1 (en) * | 2024-06-12 | 2025-12-18 | Sirtsei Pharmaceuticals, Inc. | Compositions and methods for treating retinal diseases or conditions |
| WO2026073064A1 (en) * | 2024-09-30 | 2026-04-02 | Invirsa, Inc. | 5'-adenosine diphosphate ribose (adpr) for use in improving visual acuity |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04273826A (ja) * | 1991-02-27 | 1992-09-30 | Dainippon Ink & Chem Inc | 抗ｒｓウイルス剤 |
| EP0618214A1 (en) | 1993-04-01 | 1994-10-05 | Merrell Dow Pharmaceuticals Inc. | Unsaturated phosphonate derivatives of purines and pyrimidines |
| JPH07247210A (ja) | 1994-03-09 | 1995-09-26 | Sunstar Inc | 口腔用組成物 |
| JP2001515916A (ja) | 1997-09-11 | 2001-09-25 | オクシジェン，インコーポレイテッド | 悪性および伝染性疾患の治療用にニコチンアミド・アデニン・ジヌクレオチドならびにその類似物を用いる治療法 |
| WO2000050024A2 (en) | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
| EP1192258A2 (en) | 1999-06-16 | 2002-04-03 | Icos Corporation | Human poly(adp-ribose) polymerase 2 materials and methods |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| EP1409503A1 (en) | 2001-07-25 | 2004-04-21 | Celltech R & D Limited | Non-natural carbon-linked nucleotides and dinucleotides |
| AU2003230952A1 (en) | 2002-05-21 | 2003-12-12 | Abbott Laboratories | Treatment of mucositis |
| JP2005089450A (ja) | 2003-08-11 | 2005-04-07 | Fujisawa Pharmaceut Co Ltd | Ｒｓウィルスによる感染症の予防または治療剤 |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050276762A1 (en) | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
| WO2006127987A2 (en) | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| EP1948215B1 (en) | 2005-11-14 | 2012-01-11 | Centre National De La Recherche Scientifique (Cnrs) | MacroH2A non-histone domain as inhibitor of PARP-1 activity and uses thereof |
| WO2008154129A1 (en) | 2007-06-08 | 2008-12-18 | Bausch & Lomb Incorporated | Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye |
| US20110217262A1 (en) | 2010-03-05 | 2011-09-08 | Kornfield Julia A | Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability |
| JP2013526514A (ja) | 2010-05-10 | 2013-06-24 | ラディカル・セラピューティックス・インコーポレイテッド | リポ酸およびニトロキシド誘導体およびその使用 |
| KR101967938B1 (ko) | 2011-05-12 | 2019-04-10 | 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 | 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물 |
| US20160287622A1 (en) | 2013-11-18 | 2016-10-06 | Massachusetts Institute Of Technology | Compositions and methods for treating immune and viral disorders and modulating protein-rna interaction |
| KR102622656B1 (ko) * | 2016-02-18 | 2024-01-10 | 인버사, 인크. | 5'-아데노신 디포스페이트 리보오스 (adpr)의 사용 방법 |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
-
2019
- 2019-03-26 WO PCT/US2019/023977 patent/WO2019191026A2/en not_active Ceased
- 2019-03-26 EP EP23168073.7A patent/EP4226971A1/en active Pending
- 2019-03-26 JP JP2020551992A patent/JP7242696B2/ja active Active
- 2019-03-26 US US16/364,760 patent/US10946034B2/en active Active
- 2019-03-26 EP EP19726521.8A patent/EP3773604B1/en active Active
- 2019-03-26 ES ES19726521T patent/ES2949441T3/es active Active
-
2021
- 2021-02-09 US US17/171,548 patent/US11793826B2/en active Active
-
2023
- 2023-03-08 JP JP2023035224A patent/JP7745584B2/ja active Active
- 2023-09-11 US US18/244,693 patent/US12233083B2/en active Active
-
2025
- 2025-01-17 US US19/029,481 patent/US20250161343A1/en not_active Abandoned
- 2025-05-02 JP JP2025076718A patent/JP2025118771A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519315A5 (https=) | ||
| US5789391A (en) | Method of treating sinusitis with uridine triphosphates and related compounds | |
| US6423694B1 (en) | Method of treating otitis media with uridine triphosphates and related compounds | |
| JP2023071933A5 (https=) | ||
| EP0889728B1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
| CN101495122B (zh) | 使用定量吸入器给予曲前列尼 | |
| EP0941099B1 (en) | Treatment of bronchitis with diuridine tetraphosphate | |
| JP2014518268A5 (https=) | ||
| JP2005532988A (ja) | 呼吸上皮の病変を治療するための方法および組成物 | |
| JPWO2019191026A5 (https=) | ||
| JP2019505596A5 (https=) | ||
| US6420347B1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
| BR112018074551B1 (pt) | Aerossol farmacêutico, composições farmacêuticas líquida e sólida, kit, e, método para preparar e dispensar um aerossol | |
| RU2015129076A (ru) | Арилалкил- и арилоксиалкил-замещенные соединения, блокирующие эпителиальный натриевый канал | |
| HRP20211942T1 (hr) | Medicinska uporaba 5'-adenozin difosfat riboze (adpr) | |
| CN104507918A (zh) | 用于治疗或预防肺炎病毒感染和相关疾病的组合物和方法 | |
| JP2009500354A (ja) | 肺疾患を治療するためのｐ２ｙ６受容体アゴニスト | |
| CA2701388C (en) | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions | |
| EP1941883A1 (en) | Use of sodium blockers for an early therapy of obstructive lung diseases | |
| CA3202852A1 (en) | Methods and compositions for treating chronic obstructive pulmonary disease, asthma, pneumonia, bronchitis, cystic fibrosis and pulmonary edema, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, a cute respiratory distress syndrome, and pulmonary arterial hypertension | |
| KR100549904B1 (ko) | 우리딘트리포스페이트및관련화합물을함유하는섬모운동장해치료용약학조성물 | |
| JPWO2021222740A5 (https=) | ||
| IT202000012343A1 (it) | Metotrexato per l’uso nel trattamento farmaceutico di infezioni virali del tratto respiratorio | |
| MXPA99000011A (en) | Method for treating sinusitis with trifosphates deuridine and relative compounds | |
| CN101237772A (zh) | 用于治疗肺病的p2y6受体激动剂 |